Markets:

Overview

News

Currencies

International

Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.680 -1.000 (-21.37%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

January 15, 2026

From Agenus Inc.

Via Business Wire

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

January 12, 2026

From Agenus Inc.

Via Business Wire

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

December 23, 2025

From Agenus Inc.

Via Business Wire

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

December 12, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

November 19, 2025

From Agenus Inc.

Via Business Wire

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC

November 18, 2025

From Agenus Inc.

Via Business Wire

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

November 10, 2025

From Agenus Inc.

Via Business Wire

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

November 05, 2025

From Agenus Inc.

Via Business Wire

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

October 17, 2025

From Agenus Inc.

Via Business Wire

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

October 16, 2025

From Agenus Inc.

Via Business Wire

France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

September 09, 2025

From Agenus Inc.

Via Business Wire

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 05, 2025

From Agenus, Inc.

Via Business Wire

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

August 26, 2025

From Agenus Inc.

Via Business Wire

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

August 19, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

August 11, 2025

From Agenus Inc.

Via Business Wire

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

July 31, 2025

From Agenus Inc.

Via Business Wire

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

July 25, 2025

From Agenus Inc.

Via Business Wire

Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

July 07, 2025

From Agenus Inc.

Via Business Wire

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

June 17, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces Virtual Annual Shareholders Meeting

June 10, 2025

From Agenus Inc.

Via Business Wire

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

June 03, 2025

From Agenus Inc.

Via Business Wire

Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer

May 30, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025

From Agenus Inc.

Via Business Wire

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025

From Agenus Inc.

Via Business Wire

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025

From Agenus Inc.

Via Business Wire

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

April 29, 2025

From Agenus Inc.

Via Business Wire

Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

April 28, 2025

From Agenus Inc.

Via Business Wire

Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

April 25, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

April 23, 2025

From Agenus Inc.

Via Business Wire

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

March 25, 2025

From Agenus Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.